Background: The farnesoid X receptor (FXR) regulates bile acid (BA) metabolism and possesses tumor suppressor
Introduction
The farnesoid X receptor (FXR) 7 regulates bile acid (BA) homeostasis through the enterohepatic circulation. In the intestine, FXR activates the expression of ileal bile acid-binding protein (IBABP) and small heterodimer partner (SHP). In turn, SHP represses the intestinal expression of the sodium-dependent BA transporter. In the liver, FXR induces SHP expression, which 7 Abbreviations used: APC, adenomatous polyposis coli; BA, bile acid; c-MYC, cellular myelocytomatosis; Cox-2, cyclooxygenase-2; DCA, deoxycholic acid; FAP, familial adenomatous polyposis; FXR, farnesoid X receptor; HFD, high-fat diet; IBABP, ileal bile acid-binding protein; MSP, methylation-specific primer; NT, nontumor; SHP, small heterodimer partner; siAPC, silencing RNA for adenomatous polyposis coli; Wnt, wingless-type mouse mammary tumor virus integration site family.
then inhibits the expression of the cytochrome P450 A1 enzyme that catalyzes the de novo synthesis of BA from cholesterol (1) . In human colorectal neoplasms, FXR expression becomes repressed at the late adenoma stage during the transition to carcinoma (2) and is inversely correlated with the grade of malignancy and poor clinical outcome (3) . In Fxr 2/2 knockout mice, the loss of FXR function increases susceptibility to chemically induced colon tumorigenesis (4) . Conversely, Fxr transgene overexpression in intestinal cells reduces tumor growth (5) . Thus, conditions that interfere with normal intestinal cell FXR expression and signaling may compromise normal BA homeostasis, leading to the increased production of a tumor-promoting secondary BA such as deoxycholic acid (DCA) (6) (7) (8) (9) (10) .
Intestinal expression of FXR is substantially reduced in patients with autosomal dominantly inherited familial adenomatous polyposis (FAP) (5) , which is caused by germline mutations in the adenomatous polyposis coli (APC) gene. Somatic APC mutations occur early in colorectal tumorigenesis (11) . Patients with FAP develop numerous colorectal adenomas in their first 2 decades of life that inevitably progress to colorectal cancer unless prophylactic panproctocolectomy is performed (12) . Fxr expression is reduced in the Apc Min/+ mouse (4), which carries an inactivating mutation in the Apc gene. The APC protein sequesters b-catenin in the cytosol, thereby preventing the activation of the protumorigenic wingless-type mouse mammary tumor virus integration site family (Wnt) signaling pathway (13, 14) . When APC expression is reduced, b-catenin has been shown to translocate to the nucleus and induce members of the transcription factor/lymphoid enhancer-binding factor to form transcription complexes, which in turn increase the expression of protumorigenic cyclin D1 (15, 16) and cellular myelocytomatosis (c-MYC) (17) . Although these downstream effects are understood, the initial mechanisms that link APC inactivation to reduced FXR expression remain largely unknown.
Our first objective in this study was to investigate the mechanisms that link the inactivation of Apc to reduced nuclear receptor subfamily 1, group H, member 4 (Fxr gene name) expression in colon tumors. We used the Apc Min/+ mouse because it carries mutated Apc (18) and is regarded as a good model of multistage colon carcinogenesis (19) . We extended these studies to in vitro experiments with human colon cancer cells (HCT-116) carrying wild-type APC (20) and transfected with silencing RNA for APC (siAPC) or human colon cancer cells (HT-29) harboring inactivated APC (20) and treated with DCA. We selected DCA as a prototype secondary BA because its fecal excretion increases with high-fat diet (HFD) consumption (21, 22) , and the accumulation of DCA has been linked to an increased risk of polyps and colorectal tumors (6, 7) .
Methods
Mice models. Control C57/BL6J male mice were purchased from Jackson Laboratories. Mice were killed at 12 wk of age, and colonic tissue was isolated for further analyses as described previously (23) . Briefly, the large bowel was cut open longitudinally along the main axis and washed with ice-cold PBS. Proximal colonic mucosa was scraped, and colonic cells were separated by centrifugation. Fxra 2/2 mice in pure C57BL/6J background were gifts from Frank Gonzalez (Laboratory of Metabolism, National Cancer Institute (25) . At the end of the treatment periods, cells were washed with PBS, harvested, and stored at 280°C until further analysis. DCA was purchased from Sigma-Aldrich.
qRT-PCR. Total RNA was extracted from mucosa scraped from the proximal colon according to the protocol described previously (26) and purified using the Quick-RNA MiniPrep kit according to the manufacturerÕs instructions (Zymo Research). The concentration and quality of RNA were verified using the Thermo Scientific NanoDrop1000 spectrophotometer. Equal amounts of total RNA (500 ng) were transcribed into cDNA using qScript cDNA SuperMix (Quanta Biosciences). PCR products were amplified from the cDNA fragments using PerfeCTa SYBR Green FastMix, ROX (Quanta Biosciences). Briefly, reactions were run at a final volume of 10 mL consisting of the following master mix: 5 mL of SYBR Green FastMix, 1 mL each of forward and reverse primers (10 nmol/L), 2 mL of nuclease-free water, and 1 mL of cDNA. Amplification of Gapdh (GAPDH for HCT-116 and HT-29) was used for normalizing mRNA expression. The mouse and human primers (Sigma-Aldrich) used for qRT-PCR are shown in Supplemental Table 1 .
Western blotting and silencing RNA experiments. Immunodetection by Western blotting was performed using antibodies obtained from Santa Cruz Biotechnology (H-130 FXR, b-ACTIN) and EMD Millipore (c-MYC anti-phospho Thr58/Sr62). Silencing RNA experiments were carried out according to the manufacturerÕs instructions (Dharmacon) as described previously (27) . Briefly, 5 3 10 5 HCT-116 cells were plated in 6-well plates and transfected using the DharmaFECT 2 transfection reagent with nontargeting pool and smart pool human siAPC for 48 h. Cells were then cultured in control DMEM or DMEM supplemented with 50 mmol/L DCA for an additional 72 h. At the end of the incubation period, cells were harvested for qRT-PCR and Western blotting analyses.
CpG methylation. Promoter methylation was analyzed as described previously (28) . Briefly, genomic DNA was isolated from 10-15 mg of proximal colon mucosa using the DNeasy Blood & Tissue Kit (Qiagen). Genomic DNA (1 mg) was subjected to bisulfite modification using the EpiTect Bisulfite Conversion Kit (Qiagen). In preliminary experiments, we verified that the number of cycles for semiquantitatively amplifying each promoter fragment with methylation-specific primers (MSPs) was in the linear range. The bisulfite-modified DNA was analyzed by PCR as follows: 1 cycle at 94°C for 1 min; 35 cycles at 94°C for 30 s, 59°C for 30 s, and 72°C for 1 min; and 1 cycle at 72°C for 5 min. Reactions were carried out at a final volume of 25 mL consisting of the following master mix: 50 ng of bisulfite-modified genomic DNA, 0.4 mL of JumpStart Taq DNA polymerase (Sigma-Aldrich), 2.5 mL of 103 PCR buffer, 3.5 mL of 25 mM MgCl 2 (final concentration: 3.5 mmol/L), 0.5 mL of 10 mmol/L deoxyribonucleotide triphosphate mix (final concentration: 200 mmol/L), 1 mL each of forward and reverse primers, and water to bring the final volume to 25 mL. The PCR amplification products were separated on 2% agarose gels and visualized using ethidium bromide staining. PCR amplicons were of the expected size, and their authenticity was confirmed by direct sequencing. The primers (Sigma-Aldrich) used for DNA methylation studies are shown in Supplemental Table 1 .
Statistical analysis. Densitometries of CpG-methylated FXR after PCR amplification and FXR protein after Western blotting of samples from
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HCT-116 and HT-29 cells were performed using Kodak ID image EDAS 290 analysis software (Eastman Kodak). Statistical analyses of CpG methylation and expression data from mice and cell culture studies were performed by 1-factor ANOVA after assessing data normality using a Shapiro-Wilk test and variance homogeneity using BartlettÕs test. After main effects were found to be significant at P #0.05, post hoc multiple comparisons among all means were conducted using TukeyÕs test.
Results
Apc deficiency correlates with lower Fxr expression in adjacent colonic mucosa and colon tumors. Intestinal accumulation of BA, hyperlipidemia, and reduced FXR expression have been shown to accompany the development of intestinal tumors in Apc-deficient models (4, 29) . To investigate the mechanisms that link Apc deficiency to reduced FXR expression, we first compared mRNA levels in nontumor (NT) proximal colonic mucosa of Apc Min/+ mice to those of control wild-type C57BL/6J mice. Fxr expression was 60% lower in NT mucosa from the Apc Min/+ mice than in colonic mucosa from control mice and was reduced an additional 30% in colon tumors of Apc Min/+ mice ( Figure 1 ).
Constitutive CpG methylation of Fxra3/4 promoter in Apcdeficient adjacent colonic mucosa and colon tumors. To determine whether epigenetic mechanisms contributed to reducing Fxr expression in the colonic mucosa and tumors of Apc Min/+ mice, we studied changes in Fxra3/4 CpG promoter methylation (Figure 2A, B) . We selected the promoter region on exon-3 because it generates Fxra3/4 transcripts, which are expressed in the intestine at higher levels compared with the Fxra1/2 isoforms transcribed from exon-1 (1). In FAP patients, FXRa3/4 transcripts are markedly reduced compared with FXRa1/2 variants (30). In preliminary experiments, we confirmed that amplification with MSPs of Fxra3/4 promoter fragments occurred in the linear range ( Figure 2C ). Accounting for the reduction in Fxr expression, CpG methylation of the Fxra3/4 promoter was ;0.4-fold higher in NT mucosa and ;0.8-fold higher in Apc Min/+ mouse colonic tumors compared with levels found in wild-type C57BL/6J mice ( Figure 3A) . Using MSPs, we also performed direct-sequence analyses of bisulfonated genomic DNA obtained from 4 independent DNA clones derived from 4 separate Apc Min/+ tumors. We found that 13 CpG sites flanking the transcription start site on exon-3 ( Figure 3B ) were consistently methylated. APC deficiency hampers the stimulation of FXR expression by DCA in human colon cancer cells in vitro. To further examine the impact of APC inactivation on the regulation of FXR expression, we transfected HCT-116 cells with siAPC. Compared with cells transfected with nontarget silencing RNA, a large (;80%) reduction in APC mRNA expression was accompanied by increased levels (;0.4-fold) of c-MYC transcripts ( Figure 5A ). c-MYC is a downstream target for the activated Wnt/b-catenin pathway (17) . As a positive control for tumor promotion by DCA in APC-deficient cells, we observed that the treatment of HT-29 colon cancer cells with DCA induced c-MYC protein levels (;4.0-fold) ( Figure 5B ). In HCT-116 cells transfected with siAPC, we observed a ;50% reduction in FXR mRNA levels, which were reduced by an additional 30% when exposed to DCA ( Figure 5C ).
To simulate the exposure of colon cells with wild-type APC to secondary BA in vitro, we treated human HCT-116 colon cancer cells with DCA. In response to the DCA treatment, FXR expression increased 1.5-fold in HCT-116 cells ( Figure 6A ). This was accompanied by reduced (;50%) FXR CpG methylation ( Figure 6B ) and accumulation (1.0-fold) of the FXR protein ( Figure 6C ). Conversely, DCA treatment did not elicit significant changes in FXR CpG methylation ( Figure 6B ) and FXR protein ( Figure 6C ) concentrations in HT-29 cells. Overall, these cumulative in vitro findings suggested that in human colon cells harboring wild-type APC the DCA-induced expression of FXR was associated with a reduction in FXR CpG methylation. Conversely, in APC-deficient human colon cancer cells the FXR gene was refractory to DCA stimulation in association with increased expression of the c-MYC oncogene.
Discussion
Despite widespread screening and advances in treatment, colorectal cancer remains the second cause of cancer death in the United States (31) . The FXR is a transcriptional regulator of several enterohepatic metabolic pathways (1, 32) . Importantly, reduced FXR expression is associated with intestinal tumorigenesis in human subjects (3, 5) and animal models (4, 5) .
In this study, the first objective was to examine whether changes in Fxr CpG methylation contributed to regulating Fxr expression in apparently normal colonic mucosa and colon tumors of Apc Min/+ mice. The Apc Min/+ mouse is a model of human FAP caused by mutations in the APC gene (4, 5) . We found that the region of the Adenomatous polyposis coli and farnesoid X receptor 239 methylation and Shp and Ibabp expression studies. The marked reduction in Shp and Ibabp expression in both nonneoplastic colonic mucosa, and colon tumors of Apc Min/+ mice were consistent with the fact both Shp and Ibabp genes are direct targets for transcriptional activation by FXR (1). Conversely, we attributed the activation of Cox-2 expression observed in Apc Min/+ and Apc Min/+ Fxr 2/2 mice to overriding of the negative feedback by FXR on the NF-kB/Cox-2 axis (33). Therefore, a possible implication of these findings is that changes in CpG methylation in the Fxr and Cox-2 genes could serve as sentinel biomarkers of intestinal inflammation and tumorigenesis associated with Apc inactivation. In support of this idea, early changes in CpG methylation profiles of genes involved in lipid metabolism and inflammation are being considered as epigenetic predictors of colon tumor development in humans (34) .
The Fxr CpG methylation and expression data presented in this study complement those of a recent study (35) that documented reduced FXR expression in human precancerous lesions and colon tumors. The authors of the latter study, however, did not observe any changes in FXR promoter methylation at a distal CpG island comprising 11 CpGs and spanning the 5# region upstream (;23.2 to 22.9 kb) from the transcription start site of exon-1. We focused our methylation studies on a proximal 470-bp region harboring 13 CpG dinucleotides and flanking the transcription start site of exon-3. Compared with FXRa1/2 variants, FXRa3/4 transcripts are markedly reduced in the tumors of FAP patients (30) . Therefore, APC gene inactivation in intestinal cells may lead to preferential CpG methylation in the proximal FXRa3/4 promoter. This specificity may be related to the evidence that FXRa3/4 variants are transcribed at higher amounts in the intestine (1). Moreover, the alternative usage of transcription start sites on the FXR gene and expression of FXR variants (36, 37) may be related to differential regulation at various stages of colon tumorigenesis (35) . Therefore, future studies should compare the effects of APC deficiency on CpG methylation and the expression of FXR splicing variants at various tumor stages (e.g., adenomas compared with adenocarcinomas) of colon tumor development.
The silencing of APC in human HCT-116 colon cancer cells abrogated basal FXR expression, which was reduced further upon cotreatment with DCA. These changes culminated with the upregulation of c-MYC, a downstream target for the Wnt/ b-catenin pathway (17) . In nonneoplastic mucosa of the ileum and proximal colon, APC and FXR expression has been shown to follow an increasing gradient from the bottom of the crypts to the top of the intestinal villi and luminal surface of the colonic crypts (3, 38) . These expression patterns combined with published (4, 5) and our data suggest that APC may be required for properly regulating FXR expression and the differentiation of colonic cells (39) . In support of this idea, we observed that the in vitro treatment of human HCT-116 colon cancer cells with physiological concentrations of DCA (40), a prototype secondary BA, induced FXR expression and reduced FXR CpG methylation. Although HCT-116 cells have been found to harbor 1 mutated allele for the catenin (cadherin-associated protein), b1, 88-kDa gene that encodes b-catenin, APC/b-catenin complexes are functional in these cells (20) . In contrast, in human HT-29 colon cancer cells that harbor a mutated APC gene, modest changes in FXR expression or CpG methylation were observed in response to treatment with DCA, which, however, induced c-MYC expression, a downstream target of the Wnt/ b-catenin pathway. These data are in accordance with those of earlier studies that reported constitutive activation of the Wnt/ b-catenin pathway in the small intestine of Apc Min/+ mice (41) and in immune-deficient nude mice xenografted with HT-29 colon cancer cells (42) .
Taken together, our mice data show that defective Apc expression induces CpG methylation in the Fxr gene and compromises the expression of downstream targets (e.g., Shp, Ibabp) necessary to maintain BA homeostasis. Moreover, reduced Fxr expression is accompanied by constitutive accumulation of proinflammatory Cox-2. We hypothesize that this environment may reinforce the tumor-promoting effects of secondary BAs such as DCA. The requirement for normal APC in activating FXR expression is corroborated by our in vitro observations with human colon cancer cells. Ongoing studies in our laboratory are exploring the signaling cascades through which APC inactivation modulates the placement of CpG methylation and other epigenetic marks (e.g., histone modifications) on the FXR gene and the potential effects of reduced FXR expression on the microbiome and production of secondary BAs (43) . An important question raised by the current observations is whether individuals who carry mutated (familial) or inactivated (sporadic) APC and adhere to a HFD may be at higher risk of developing colon inflammation and cancer induced by secondary BAs via reduced FXR expression. Therefore, future studies should examine the differential effects of various HFDs (e.g., n-6 compared with n-3) on FXR CpG methylation in normal and APC-deficient colon models. A second question pertains to whether other epigenetic regulatory defects associate with tumor development in APC-deficient colon cells. Recent studies conducted in the Apc Min/+ model provided evidence that tumor-related hypermethylation appeared as a progressive event and reached higher levels in advanced tumor stages (44, 45) . Consequently, progress in understanding the mechanisms responsible for DNA methylation dynamics in the Fxr and other genes may unravel how interactions between the inactivation of APC and exposure to dietary FAs influence the risk of inflammatory bowel diseases (46, 47) and colorectal tumors (42, 48) and thus offer new epigenetic targets for diagnosis and prevention.
